# Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

> **NCT01811212** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Poorly Differentiated Thyroid Gland Carcinoma
- Recurrent Thyroid Gland Carcinoma
- Stage I Thyroid Gland Follicular Carcinoma
- Stage I Thyroid Gland Papillary Carcinoma
- Stage II Thyroid Gland Follicular Carcinoma
- Stage II Thyroid Gland Papillary Carcinoma
- Stage III Thyroid Gland Follicular Carcinoma
- Stage III Thyroid Gland Papillary Carcinoma
- Stage IVA Thyroid Gland Follicular Carcinoma
- Stage IVA Thyroid Gland Papillary Carcinoma
- Stage IVB Thyroid Gland Follicular Carcinoma
- Stage IVB Thyroid Gland Papillary Carcinoma
- Stage IVC Thyroid Gland Follicular Carcinoma
- Stage IVC Thyroid Gland Papillary Carcinoma
- Tall Cell Variant Thyroid Gland Papillary Carcinoma
- Thyroid Gland Oncocytic Follicular Carcinoma

## Interventions

- **DRUG:** Cabozantinib S-malate
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01811212
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-08
- **Primary completion:** 2015-07-13
- **Final completion:** 2017-10-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01811212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01811212, "Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT01811212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*